Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial

被引：0
|
作者：
Ferreira, J. P. [1 ]
Verma, S. [2 ]
David, F. [3 ]
Ofstad, A. P. [4 ]
Lauer, S. [5 ]
Zwiener, I. [5 ]
George, J. T. [6 ]
Wanner, C. [7 ]
Zinman, B. [8 ]
Inzucchi, S. E. [9 ]
机构：
[1] Univ Lorraine, Inserm 1433, Ctr Invest Clin Plurithemat, Nancy, France
[2] Univ Toronto, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Boehringer Ingelheim Norway KS, Asker, Norway
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Wurzburg Univ Clin, Wurzburg, Germany
[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[9] Yale Univ, Sch Med, New Haven, CT USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
947
引用
收藏
页码：S450 / S451
页数：2
相关论文
共 50 条
  • [1] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    Ferreira, Joao Pedro
    Verma, Subodh
    Fitchett, David
    Ofstad, Anne Pernille
    Lauer, Sabine
    Zwiener, Isabella
    George, Jyothis
    Wanner, Christoph
    Zinman, Bernard
    Inzucchi, Silvio E.
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [2] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    João Pedro Ferreira
    Subodh Verma
    David Fitchett
    Anne Pernille Ofstad
    Sabine Lauer
    Isabella Zwiener
    Jyothis George
    Christoph Wanner
    Bernard Zinman
    Silvio E. Inzucchi
    Cardiovascular Diabetology, 19
  • [3] THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME
    Verma, Subodh
    Wanner, Christoph
    Zwiener, Isabella
    Ofstad, Anne Pernille
    George, Jyothis T.
    Fitchett, David
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 2037 - 2037
  • [4] THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME
    Verma, S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E193 - E193
  • [5] Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME
    Verma, S.
    Mazer, C. D.
    Inzucchi, S. E.
    Wanner, C.
    Ofstad, A. P.
    Johansen, O. E.
    Zwiener, I
    George, J. T.
    Butler, J.
    Zinman, B.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3352 - 3352
  • [6] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
  • [7] Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
    McGuire, Darren K.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Fitchett, David
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    von Eynatten, Maximilian
    Johansen, Odd Erik
    Jamal, Waheed
    Mattheus, Michaela
    Elsasser, Ulrich
    Hantel, Stefan
    Lund, Soren S.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 949 - 959
  • [8] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
    Verma, Subodh
    Leiter, Lawrence A.
    Zinman, Bernard
    Sharma, Abhinav
    Mattheus, Michaela
    Fitchett, David
    George, Jyothis
    Ofstad, Anne Pernille
    Kosiborod, Mikhail N.
    Wanner, Christoph
    Inzucchi, Silvio E.
    ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607
  • [9] Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial
    Ferreira, Joao Pedro
    Inzucchi, Silvio E.
    Mattheus, Michaela
    Meinicke, Thomas
    Steubl, Dominik
    Wanner, Christoph
    Zinman, Bernard
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 135 - 141
  • [10] Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
    Vaduganathan, M.
    Sattar, N.
    Fitchett, D.
    Ofstad, A.
    Brueckmann, M.
    George, J. T.
    Verma, S.
    Mattheus, M.
    Wanner, C.
    Inzucchi, S. E.
    Zinman, B.
    Butler, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S275 - S275
12345